Evaluating the Next Steps for Research in Myelofibrosis
Laura Michaelis, MD, discusses the next steps for research in the treatment of myelofibrosis following the addition of fedratinib (Inrebic) to the armamentarium of JAK inhibitors.
Related Articles
Optimizing Anemia Management in LR-MDS: Key Takeaways and Unmet Needs
Jamie Koprivnikar, MD, provides key takeaways for optimizing anemia management in patients with lower-risk MDS, highlighting unmet needs in treating anemia and improving patient outcomes.
Positive Responses Are Reported for Fianlimab/Cemiplimab in ccRCC
Fianlimab plus cemiplimab was well-tolerated and showed durable responses, in pretreated patients with advanced clear cell renal carcinoma.
Therapy Changes for Metastases and Toxicity Discussed in Breast Cancer
During a Case-Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment toxicity would affect therapy given…
Novel Bispecific Antibody Fusion Protein Earns FDA Fast Track in Melanoma
IBI363 has earned fast track designation from the FDA for the treatment of previously treated unresectable advanced melanoma.
Clinical Benefits of Luspatercept Dose Titration: Real-World Evidence
An expert on the treatment of patients with myelodysplastic syndromes provides clinical insights on dosing practices and considerations for luspatercept.
Transplant in ALL: Tailoring Treatment Based on MRD
Partow Kebriaei, MD, discusses transplant in acute lymphoblastic leukemia.
Enhancing Cancer Diagnosis With AI Algorithms in Pathology
Anil Parwani, MD, PhD, discusses the use of artificial intelligence technology to enhance cancer diagnostics and treatment.
FDA Approves Ready-to-Use Subcutaneous Bortezomib Formulation
The ready-to-use formulation of bortezomib is now an FDA-approved option for patients with multiple myeloma and mantle cell lymphoma.
Sequencing Therapies in R/R Mantle Cell Lymphoma
Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual…
Moving TKIs to the Front-Line in CML-CP Requires Improved OS and Cost-Effective Strategies
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.